Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors
Febrile neutropenia is a serious chemotherapy-related adverse event that can lead to complications and death and it could be a significant burden on the organization of the health care system. The risk for febrile neutropenia is determined by chemotherapy-induced myelosuppression and the presence of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Belgrade, Medical Faculty
2022-01-01
|
| Series: | Medicinski Podmladak |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2022/0369-15272202001D.pdf |
| _version_ | 1828328268992872448 |
|---|---|
| author | Dimitrijević Jelena Stojanović Marko |
| author_facet | Dimitrijević Jelena Stojanović Marko |
| author_sort | Dimitrijević Jelena |
| collection | DOAJ |
| description | Febrile neutropenia is a serious chemotherapy-related adverse event that can lead to complications and death and it could be a significant burden on the organization of the health care system. The risk for febrile neutropenia is determined by chemotherapy-induced myelosuppression and the presence of patient-related risk factors. In the literature, various patient-related risk factors are taken into consideration. It was suggested that the patient age is the one of the most important ones. If the estimated risk for the febrile neutropenia is high, prophylactic use of myeloid growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor) is recommended. In patients with solid tumors and lymphomas it was shown that the prophylactic use of myeloid growth factors significantly reduces the incidence of febrile neutropenia, early mortality during chemotherapy and infection-induced mortality. In patients who develop febrile neutropenia, there is less evidence for the therapeutic use of myeloid growth factors compared to prophylactic use, although there is a clear benefit in reducing the time to neutrophil count recovery. There is a clear benefit for hospitalized patients, also, in reducing duration of hospitalization. In patients with febrile neutropenia who have not been previously treated with prophylactic myeloid factors, assessment of risk factors for the complications is advised. In patients with high-risk febrile neutropenia therapeutic use of growth should be considered. |
| first_indexed | 2024-04-13T20:06:15Z |
| format | Article |
| id | doaj.art-cd83e155e11e49aaa9bc510744621689 |
| institution | Directory Open Access Journal |
| issn | 0369-1527 2466-5525 |
| language | English |
| last_indexed | 2024-04-13T20:06:15Z |
| publishDate | 2022-01-01 |
| publisher | University of Belgrade, Medical Faculty |
| record_format | Article |
| series | Medicinski Podmladak |
| spelling | doaj.art-cd83e155e11e49aaa9bc5107446216892022-12-22T02:31:58ZengUniversity of Belgrade, Medical FacultyMedicinski Podmladak0369-15272466-55252022-01-017321510.5937/mp73-367800369-15272202001DProphylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factorsDimitrijević Jelena0Stojanović Marko1https://orcid.org/0000-0003-2097-7591Institut za onkologiju i radiologiju Srbije, Beograd, SerbiaUniverzitet u Beogradu, Medicinski fakultet, Institut za farmakologiju, kliničku farmakologiju i toksikologiju, Beograd, SerbiaFebrile neutropenia is a serious chemotherapy-related adverse event that can lead to complications and death and it could be a significant burden on the organization of the health care system. The risk for febrile neutropenia is determined by chemotherapy-induced myelosuppression and the presence of patient-related risk factors. In the literature, various patient-related risk factors are taken into consideration. It was suggested that the patient age is the one of the most important ones. If the estimated risk for the febrile neutropenia is high, prophylactic use of myeloid growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor) is recommended. In patients with solid tumors and lymphomas it was shown that the prophylactic use of myeloid growth factors significantly reduces the incidence of febrile neutropenia, early mortality during chemotherapy and infection-induced mortality. In patients who develop febrile neutropenia, there is less evidence for the therapeutic use of myeloid growth factors compared to prophylactic use, although there is a clear benefit in reducing the time to neutrophil count recovery. There is a clear benefit for hospitalized patients, also, in reducing duration of hospitalization. In patients with febrile neutropenia who have not been previously treated with prophylactic myeloid factors, assessment of risk factors for the complications is advised. In patients with high-risk febrile neutropenia therapeutic use of growth should be considered.https://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2022/0369-15272202001D.pdffebrile neutropeniacolony-stimulating factorsprophylactic usetherapeutic use |
| spellingShingle | Dimitrijević Jelena Stojanović Marko Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors Medicinski Podmladak febrile neutropenia colony-stimulating factors prophylactic use therapeutic use |
| title | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors |
| title_full | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors |
| title_fullStr | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors |
| title_full_unstemmed | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors |
| title_short | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors |
| title_sort | prophylaxis and management of chemotherapy induced febrile neutropenia the role of myeloid growth factors |
| topic | febrile neutropenia colony-stimulating factors prophylactic use therapeutic use |
| url | https://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2022/0369-15272202001D.pdf |
| work_keys_str_mv | AT dimitrijevicjelena prophylaxisandmanagementofchemotherapyinducedfebrileneutropeniatheroleofmyeloidgrowthfactors AT stojanovicmarko prophylaxisandmanagementofchemotherapyinducedfebrileneutropeniatheroleofmyeloidgrowthfactors |